Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Hutchmed China launches two cancer treatment trials
(Sharecast News) - Hutchmed China announced the start of two significant clinical trials on Tuesday, aimed at addressing critical unmet needs in cancer treatment. The AIM-traded firm first announced the launch of a phase two and three trial evaluating the efficacy of a combination therapy for metastatic pancreatic ductal adenocarcinoma (PDAC) in collaboration with Jiangsu Hengrui Pharmaceuticals.
It said the trial would focus on assessing the potential of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine as a first-line treatment.
Hutchmed described PDAC as a highly aggressive form of cancer with a dismal five-year survival rate, which affected over 90% of pancreatic cancer cases globally.
The trial aimed to enrol patients who had not undergone prior systemic anti-tumour therapy and would assess endpoints such as overall survival, objective response rate, and safety parameters.
"Emerging data including those from an investigator-initiated study presented at the ASCO Gastrointestinal Cancers Symposium demonstrated that combinations of surufatinib, camrelizumab and chemotherapy have promising efficacy in comparison with existing chemotherapy-based treatments in metastatic PDAC," said Hutchmed's chief executive and chief scientific officer, Dr Weiguo Su.
"We hope that this partnership will enable us to bring new, potentially life-changing treatment options to patients."
In the second announcement, Hutchmed unveiled the start of the 'RAPHAEL' phase three trial for HMPL-306 in patients with mutated isocitrate dehydrogenase (IDH) 1 or 2 relapsed/refractory acute myeloid leukaemia (AML).
It said HMPL-306, a dual-inhibitor of IDH1 and IDH2 enzymes, targets mutations implicated in various malignancies.
The trial was designed to evaluate its safety and efficacy as a monotherapy against current salvage chemotherapy regimens.
With mutations in IDH1 and IDH2 identified as drivers of AML and other cancers, HMPL-306 presented a promising approach to overcome acquired resistance to single IDH inhibitors, Hutchmed explained.
At 1244 BST Hutchmed China shares were down 1.14% at 346p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.